Psychedelic drugs may reopen critical learning periods in the brain.
Recent research shows that in adult mice, psychedelic drugs including LSD, ketamine and psilocybin have been shown to reopen the brain to a critical window for social learning usually only seen in adolescents.
Read more
The psychedelic space has grown rapidly and quickly led to disagreements, attempts at profiting and patenting.
A recent psychedelic conference showed there is a widening rift in the community.
Read more
Compass Pathways published the long awaited results of its phase 2 clinical trial for the treatment of depression with psilocybin–assisted psychotherapy in the New England Journal of Medicine.
Psilocybin showed rapid antidepressant effects for most patients, but only 1 in 5 participants showed significant improvement at 12 weeks.
Read more
The harms of psychedelics need to be put Into context.
As psychedelic therapy trials get bigger and the drugs become more accessible, researchers need to start talking about their potential adverse effects.
Read more
Reports of the clinical effects of psychedelic therapy — loosening memories and habits that are deeply embedded — are stacking up.
Read more
Psychedelic drugs can induce mind-altering states affecting perception, thought and sensory input.
They have historically been known for their recreational use and do not have nationwide legal approval.
However, psychedelic drugs are also increasingly being studied for their medical benefits (particularly with regard to mental health).
Learn more below about how certain psychedelics can—and cannot—be used for mental wellness.
Read more